engleski

Effects of pentadecapeptide BPC-157 on rat calvarial bicortical defects

Gastric pentadecapeptide BPC-157 (currently in clinical phase II for inflammatory bowel disease) was tested in 7 mm diameter surgically created defects of rat calvaria. Insufficient or absence of bone healing is a frequent problem within all surgical fields. This often necessitates treatment by various bone grafting procedures, utilization of osteopromotive membrane techniques, or local delivery of growth-stimulatory factors. Based on the previously recognized positive osteogenic results for gastric pentadecapeptide BPC-157 on non-union fracture, segmental osteoperiosteal bone defect, its pure peptidergic effect with no carrier interference, together with gastric epithelial cells induced osteogenesis, and a hypothetical gastric hormone opposing bone disturbances development (Bone 24 195, 1999), the aims of the present study were to further develope a possibility of osteopromotion by various routes. Rats received agents locally, BPC 157 2 microg, 2 ng/ml or saline, 1 ml bath, at the injury or intraperitoneally once daily BPC 157 10 microg, 10 ng or 10 pg/kg or saline 5.0 ml/kg, first application immediately following injury, last 24 h before sacrifice (3, 7, 14, 21 days post-injury). Both microscopical and densitometry investigation reveal gastric pentadecapeptide BPC-157 improvement of healing of rat calvarial bicortical defect at all of the tested intervals (p<0.01). In conclusion, these results indicate along with our previous result in rabbit pseudoarthrosis this suitably stable gastric pentadecapeptide BPC-157 given either system or by local application may be beneficial also calvarial defect healing.

bicortical defect; BPC-157

nije evidentirano